Fig 1
Conductance derived pressure volume loop in human right ventricle. Hatched area represents ventricular stroke work (SW) used to interrogate ventricular performance

Abstract S41 Figure 1

Methods We have followed the Oxford cohort of 189 patients for two years to assess real vascular event rates and the incidence of accidents and hospital admissions. The events have been verified by inspection of hospital notes and phone calls to patients. The CPAP/No CPAP allocation was based on intention to treat. At the end of the original 6 month trial, 71% of patients, initially randomised to CPAP, stated an intention to continue CPAP.

Results The table shows the 2 year incidence of accidents at home, work and driving (66/189), the incidence of new vascular events (25/189), and all cause mortality (4/189).

Conclusions The event rates are moderate, and there is no statistically significant difference between the groups. A power calculation, based on these figures, suggests that in order not to miss a 30% reduction in relative risk over 2 years (4% absolute reduction), with 90% power, would require 2,540 patients randomised; for accidents, 880; for mortality over 6,000.

Abstract S42 Table 1 Summary of the 2 year accident and vascular event incidence in Oxford MOSAIC patients

	Where	No CPAP	CPAP	Total
Accidents	Home	22	25	47
	Work	4	5	9
	Driving	6	4	10
	Total	32	34	66
Vascular events	Cardiovascular death	2	1	3
	Other events	15	7	22
	Total	17	8	25
All cause mortality		3	1	4

S43 FRACTAL ANALYSIS OF WHOLE BLOOD INCIPIENT CLOT CONFIRMS AN EARLY MORNING PROTHROMBOTIC STATE IN PATIENTS WITH UNTREATED OBSTRUCTIVE SLEEP APNOEA SYNDROME

doi:10.1136/thoraxjnl-2012-202678.049

¹M Wilczynska, ¹K Lewis, ²M Lawrence, ²S Stanford, L Nicolle¹, ²PA Evans. ¹Prince Philip Hospital, Swansea, UK; ²Morrison Hospital, Swansea, UK

Introduction Obstructive sleep apnoea syndrome (OSAS) independently increases cardiovascular risk and a pro-thrombotic state has

been at least partly implicated. Using fractal analysis we have developed a new biomarker called fractal dimension (**Df**) to assess the microstructure of incipient clot in whole blood. **Df** relates to the kinetics of clot formation and quantifies clot fibrin network microstructure as it forms. A higher **Df** represents a more pro-coagulable state. Healthy volunteers have a reproducible **Df** of 1.74 ± 0.07 . (1)

Aim To see if **Df** changes after sleep in OSAS and symptomatic snorers.

Methods 28 patients with newly diagnosed and untreated OSAS: 24 males, mean $\pm$ SD BMI = 38 ± 7.3 kg/m², age 56.8 ± 10.7 years, 4% Dip-rate (DR) = 47.8 ± 32.9 events/hour, Epworth Sleepiness Score (ESS) 13.1 ± 5.0 . 17 symptomatic Controls with symptoms of OSAS but who had negative sleep studies: 14 males, BMI = 32.1 ± 6.8 kg/m², age 52.7 ± 13.6 years, 4% DR = 5.6 ± 3.2 events/hour, ESS 11.3 ± 6.6 . We excluded anyone on warfarin, heparin or with a family history of bleeding, thromboses. 36% in the OSAS group and 24% in the Controls were prescribed aspirin but there were no changes in medications throughout the study. Blood was collected at 4pm then 8am the following morning, immediately after an inpatient limited channel overnight sleep study (Visilab, Stowood Instruments, UK). Samples were tested for fractal analysis (AR-G2 Rheometer, TA Instruments, UK) and routine APTT, PT, fibrinogen levels, platelet aggregation. NCT01525160.

Results **Df** was significantly higher in the early am (post sleep) ($p < 0.001$) than in the afternoon in OSAS but there was no diurnal variation in the Control group ($p = \text{NS}$) Figure 1. There were no statistically significant differences for routine coagulation and platelet function tests both within and between groups.

Conclusion OSAS is associated with a significantly increased pro-thrombotic state in the morning that is only detected by **Df**. Larger numbers will allow sub-group analyses (e.g. severity of OSAS, aspirin effects) and seeing possible response to CPAP therapy. This preliminary data suggest **Df** could be used as a new sensitive biomarker to assess vascular risk.

Reference

1. Evans PA et al. *Blood*. 2010; 116:3341–3346.

Abstract S43 Figure 1

S44 7 DAYS ACTIGRAPHY MONITORING IS EQUIVALENT TO 14 DAYS ACTIGRAPHY MONITORING IN PATIENTS WITH SLEEP DISORDERS

doi:10.1136/thoraxjnl-2012-202678.050

¹S Briscoe, ²E Hardy, ¹C Kosky, ¹A Williams, ¹N Hart, J Steier. ¹Guy's and St Thomas' NHS Foundation Trust, London, UK; ²King's College London, London, UK

Introduction Actigraphy is a valid measure to assess sleep and circadian rhythm abnormalities. It is listed in the diagnostic criteria